AKT1 and neoplasm: Hence, careful design and selection of alternate molecular inhibitors or delivery methods that target PKC and the PI3K/AKT networks need to be explored to potentiate dose reduction, widen the therapeutic window, and induce effective blockade of these survival networks in UM tumours.